GlassScriptPhysician profile
Robert Phillip Fleischer
NPI 1689651507
$3,525.27
in general payments reported to CMS, 2019-2025
25 companies · $499 in 2025
The $499 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2021: $51.86 · 2022: $79.97 · 2023: $1,829 · 2024: $697 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759 · Travel and Lodging: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.25 |
| Travel and Lodging | $1,266.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,814.40 | 2019-2024 | Lumenis Pulse 120h, Lithovue |
| Procept Biorobotics Corporation | $563.14 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Myriad Genetic Laboratories, INC. | $212.31 | 2023-2025 | Prolaris, Myrisk |
| Dendreon Pharmaceuticals LLC | $111.40 | 2022-2023 | Provenge |
| Amgen INC. | $105.63 | 2019 | |
| Olympus America INC. | $86.44 | 2024-2025 | Hd Camera Head, Cysto-Nephro Videoscope, Itind System |
| Astellas Pharma US INC | $70.27 | 2024-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $66.18 | 2019-2023 | Keytruda, Lynparza |
| Tolmar, INC. | $62.64 | 2024-2025 | Eligard, Jatenzo |
| Abbvie INC. | $62.41 | 2022-2024 | |
| Ambu INC. | $47.94 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $41.67 | 2025 | |
| Sumitomo Pharma America, INC. | $38.38 | 2023-2025 | Orgovyx |
| Immunitybio, INC. | $37.09 | 2024-2025 | |
| Blue Earth Diagnostics | $26.77 | 2025 | Posluma |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.18 | 2022 | |
| Ferring Pharmaceuticals INC. | $20.15 | 2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $19.01 | 2023 | Xiaflex |
| Progenics Pharmaceuticals, INC. | $18.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.14 | 2022 | |
| Shionogi INC | $16.97 | 2024 | Fetroja |
| Myovant Sciences INC. | $14.62 | 2021 | |
| Axonics, INC. | $13.75 | 2024 | Axonics, Bulkamid |
| Allergan, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fleischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.